Trellus Health Deepens Pharma and CRO Ties as TrialSet™ Deployment Gathers Pace

Trellus Health PLC ( (GB:TRLS) ) has shared an announcement.

Trellus Health reported ongoing operational progress across its key verticals, particularly in clinical trials, where it signed 12‑month contracts with global CROs ICON and PSI to deploy its Trellus TrialSet™ solution in Takeda- and Sanofi-sponsored immunology and inflammation studies, and maintained its support of an AstraZeneca Phase 2 IBD trial. The company also advanced pharmaceutical and patient support programmes, including continued collaboration with Johnson & Johnson Health Care Systems and a renewed content licensing deal with Pfizer, while broadening enrolment channels and exploring further expansion. Trellus is enhancing its platforms, making TrialSet™ condition-agnostic and upgrading Trellus Elevate®, alongside data protection and compliance work, which strengthens its positioning as a scalable digital health partner for pharma and CROs. Financially, Trellus expects 2025 revenue of about $545,000, has reduced monthly cash burn to roughly $400,000, and has drawn on a £5 million convertible facility with Alumni Capital, extending its cash runway into late Q1 2026 as the board pursues additional funding and seeks to convert growing clinical and commercial validation into broader market adoption.

The most recent analyst rating on (GB:TRLS) stock is a Hold with a £0.96 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.

Spark’s Take on GB:TRLS Stock

According to Spark, TipRanks’ AI Analyst, GB:TRLS is a Neutral.

The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.

To see Spark’s full report on GB:TRLS stock, click here.

More about Trellus Health PLC

Trellus Health plc is a UK- and US-based healthcare company focused on value-based digital solutions for complex chronic conditions, initially targeting high-cost gastrointestinal diseases such as inflammatory bowel disease. Its core offering, Trellus Elevate®, combines a proprietary resilience-based, behavioural science methodology with data analytics, coaching and educational tools to support whole-person condition management, while Trellus TrialSet™ applies the same platform to improve clinical trial recruitment, adherence and long-term patient engagement for pharmaceutical partners.

Average Trading Volume: 1,357,975

Technical Sentiment Signal: Buy

Current Market Cap: £1.53M

See more insights into TRLS stock on TipRanks’ Stock Analysis page.